Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H. Uryu K, et al. Jpn J Clin Oncol. 2024 Dec 1:hyae167. doi: 10.1093/jjco/hyae167. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39673402
Inflammation‑based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl‑world Data project 02 (TREAD 02).
Shimoyama R, Imamura Y, Uryu K, Mase T, Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N, Minami H. Shimoyama R, et al. Among authors: uryu k. Mol Clin Oncol. 2024 Oct 3;21(6):90. doi: 10.3892/mco.2024.2788. eCollection 2024 Dec. Mol Clin Oncol. 2024. PMID: 39421231 Free PMC article.
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H. Hibino M, et al. Among authors: uryu k. Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20. Target Oncol. 2024. PMID: 39302602 Free PMC article.
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Shimada T, Tsuya A, Fukuoka M, Minami H. Uryu K, et al. Cancer Chemother Pharmacol. 2024 Aug;94(2):197-208. doi: 10.1007/s00280-024-04666-4. Epub 2024 Apr 8. Cancer Chemother Pharmacol. 2024. PMID: 38584202
Developing inhibitory peptides against SARS-CoV-2 envelope protein.
Bekdash R, Yoshida K, Nair MS, Qiu L, Ahdout J, Tsai HY, Uryu K, Soni RK, Huang Y, Ho DD, Yazawa M. Bekdash R, et al. Among authors: uryu k. PLoS Biol. 2024 Mar 14;22(3):e3002522. doi: 10.1371/journal.pbio.3002522. eCollection 2024 Mar. PLoS Biol. 2024. PMID: 38483887 Free PMC article.
150 results